Drugs / MEDI4212
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01544348 | Jan 2012 → Jun 2013 | allergic asthma, allergic rhinitis, atopic eczema | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI4212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01544348 ↗ |
| Action | Inhibit | “MEDI4212 rapidly suppressed free serum IgE to a greater extent than omalizumab” PMID 26843086 ↗ Feb 20161“Ig epsilon chain C region inhibitor” CHEMBL2109452 ↗ |
| Modality | Monoclonal antibody | “Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.” PMID 26843086 ↗ Feb 2016 |
| Route | Intravenous | “a single dose of subcutaneous (5, 15, 60, 150, or 300 mg) or intravenous (300 mg) MEDI4212” PMID 26843086 ↗ Feb 2016 |
| Route | Subcutaneous | “a single dose of subcutaneous (5, 15, 60, 150, or 300 mg) or intravenous (300 mg) MEDI4212” PMID 26843086 ↗ Feb 2016 |
| Target | IGHE | “Ig epsilon chain C region inhibitor” CHEMBL2109452 ↗ |